TargetBeta
AGTR2
angiotensin II receptor type 2 · also AT2, MRX88 · Angiotensin receptors
2 programs in company-led studies act on AGTR2, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| LY4065967 | Eli Lilly | phase 2 | 74 running | – | the company's pipeline |
| TRD205 | Sino Biopharmaceutical | phase 2 | 54 running | – | the company's pipeline |
Conditions their studies are in
- Neuralgia, 2 programs
- Chronic Pain, 1 program
- Hallux Valgus, 1 program
- Osteoarthritis, Knee, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 2027LY4065967 · Eli Lilly · phase 2 · NCT05986292
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.